Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2017 16:05 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Closes the Sale of its Remaining Interest in PCT to Hitachi Chemical for $75 Million

BASKING RIDGE, N.J., May 18, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a clinical stage development company with a cell therapy pipeline...
May 15, 2017 17:06 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces 2017 First Quarter Financial Results

BASKING RIDGE, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a therapeutic development pipeline focused...
May 09, 2017 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Host 2017 First Quarter Financial Results Conference Call on May 18, 2017 at 5:00 p.m. Eastern Time

BASKING RIDGE, N.J., May 09, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a therapeutic development pipeline focused...
May 01, 2017 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Participate at Upcoming May Conferences

BASKING RIDGE, N.J., May 01, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline...
April 10, 2017 16:01 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Hold 2017 Annual Stockholder Meeting on May 16

BASKING RIDGE, N.J., April 10, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development...
April 05, 2017 07:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Participate at Upcoming April Conferences

BASKING RIDGE, N.J., April 05, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development...
April 03, 2017 07:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces Addition of Four Clinical Sites, Including Joslin Diabetes Center, for the Ongoing Phase 2 Study of CLBS03 in T1D

BASKING RIDGE, N.J., April 03, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company advancing a select therapeutic development...
March 17, 2017 07:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results

Annual revenue growth of 57% exceeds 2016 financial guidance Conference call begins today at 8:30 am Eastern time BASKING RIDGE, N.J., March 17, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences,...
March 16, 2017 19:30 ET | Source: Caladrius Biosciences, Inc.

Hitachi Chemical Signs Agreement to Purchase from Caladrius Biosciences the Remaining 80.1% Interest in PCT for $75 Million

Caladrius expected to emerge as a well-capitalized cell therapeutics-only development company with multiple proprietary technology platforms Conference call begins tomorrow, March 17, 2017 at 8:30 am...
March 13, 2017 07:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Host 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 17, 2017 at 8:30 am Eastern Time

BASKING RIDGE, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development...